Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Zogenix, Inc. (NASDAQ: ZGNX).

Full DD Report for ZGNX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ZGNX)

Zogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference
EMERYVILLE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive V...
Source: GlobeNewswire
Date: May, 14 2018 08:00
Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
Zogenix's (ZGNX) CEO Stephen Farr on Q1 2018 Results - Earnings Call Transcript
Zogenix, Inc. (ZGNX) Q1 2018 Earnings Conference Call May 09, 2018, 16:30 ET Executives Brian Ritchie - MD, LifeSci Advisors Stephen Farr - Co-Founder, CEO, President & Director Michael Smith - EVP, CFO, Treasurer, Secretary & Principal Accounting Officer Gail Farfel - ...
Source: SeekingAlpha
Date: May, 09 2018 21:53
Zogenix misses by $0.13
Zogenix (NASDAQ: ZGNX ): EPS of -$0.87 misses by $0.13 . Cash and equivalents of $272M. Press Release More news on: Zogenix, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 09 2018 16:06
Zogenix Provides Corporate Update and Reports First Quarter Financial Results
Following receipt of Breakthrough Therapy Designation, conducted successful Type B meeting with FDA confirming adequacy of Phase 3 program for ZX008 NDA in Dravet syndrome Study 1504 fully enrolled with 87 randomized patients; top-line results expected late June/early July ...
Source: GlobeNewswire
Date: May, 09 2018 16:01
Notable earnings after Wednesday's close
AG , ALB , AMPH , ANGI , ATUS , AYX , BLDR , BOLD , BREW , COLL , CPA , CTL , CVNA , DAR , DNB , EEP , ELF , ENV , ETE , ETP , EVH , FG , FGEN , FNGN , FNV , FOXA , FSM , FTI , FTK , GDOT , GKOS , HLI , IAC , ICUI , INFN , MBI , MELI , MRAM , MTRX , N...
Source: SeekingAlpha
Date: May, 08 2018 17:35
Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9
EMERYVILLE, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2...
Source: GlobeNewswire
Date: May, 04 2018 08:00
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to six new non-executive employees.  ...
Source: GlobeNewswire
Date: May, 01 2018 17:00
Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome
ZX008 Patients Experienced Significant Improvements on Select Measures of Quality of Life and Executive Function Compared to Those on Placebo Data Presented During Emerging Therapies Plenary Session at 2018 American Academy of Neurology Annual Meeting EMERYVILLE, Calif., April 27, ...
Source: GlobeNewswire
Date: April, 27 2018 08:00
Report: Exploring Fundamental Drivers Behind Urban Edge Properties, FLIR, Zogenix, Watts Water Technologies, CDW, and BMC Stock - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Urban Edge Properties (NYSE:UE), FLIR Systems, Inc. (NASDAQ:FLIR), Zogen...
Source: GlobeNewswire
Date: April, 25 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1739.7039.9540.7539.601705,232
2017-03-108.809.759.758.50320,699
2017-03-099.409.559.759.35248,683
2017-03-089.459.409.7259.35139,564
2017-03-079.659.409.67719.15154,824

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-16133,984216,18461.9768Short
2018-08-1592,196279,19433.0222Cover
2018-08-1444,208135,25432.6852Cover
2018-08-1369,637132,47952.5646Short
2018-08-1088,056157,87055.7775Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ZGNX.


About Zogenix, Inc. (NASDAQ: ZGNX)

Logo for Zogenix, Inc. (NASDAQ: ZGNX)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $741,897,112 - 05/11/2018
    • Issue and Outstanding: 19,170,468 - 07/01/2015

     


    Recent Filings from (NASDAQ: ZGNX)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 09 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 09 2018
    Securities offered to employees under employee benefit plans
    Filing Type: S-8Filing Source: edgar
    Filing Date: May, 09 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 13 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 13 2018
    Filing Type: CT ORDERFiling Source: edgar
    Filing Date: March, 06 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 06 2018
    Annual report with a comprehensive overview of the company
    Filing Type: 10-KFiling Source: edgar
    Filing Date: March, 06 2018
    Amendment to the SC 13G filing
    Filing Type: SC 13G/AFiling Source: edgar
    Filing Date: February, 14 2018
    Amendment to the SC 13G filing
    Filing Type: SC 13G/AFiling Source: edgar
    Filing Date: February, 14 2018

     

     


    Daily Technical Chart for (NASDAQ: ZGNX)

    Daily Technical Chart for (NASDAQ: ZGNX)


    Stay tuned for daily updates and more on (NASDAQ: ZGNX)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: ZGNX)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ZGNX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ZGNX and does not buy, sell, or trade any shares of ZGNX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/